A Randomized Phase 2 Study of CBX-12 in Subjects with Platinum Resistant or Refractory Ovarian Cancer

• CBX-12 is an alphalex construct which contains exatecan as the pharmacologically active moiety.

In this study, the sponsor and investigators want to learn:
• How the study drug / agent is acting on your cancer
• How much of the study drug can be given with an acceptable level of side effects
• The effects of the study drug (good and bad)
• How much of the study drug / agent is absorbed into the blood and how fast it is removed

In this study, research participants will be assigned to receive the study drug at one of the two doses: 100 mg/m² or 125 mg/m². The assignment is random, similar to flipping a coin.

The study regimen will be given in cycles. Each cycle is 3 weeks (21 days). You will receive the study drug once every 3 weeks in your vein through an intravenous line (IV) over about 60 minutes.